IGF1 and cancer: As a result, the type of broader evidence currently available to support IGF-I’s role in cancer, suggesting foreseeable advantages in IGF-I targetability compared to the single block of big-IGF-II in cancer, are highly debatable unless and until this is differently demonstrated using appropriate experimental design (namely with selective IGF-I and IGF-II ligands block and using positional biology multi-plex, or better, multi-omic methods to pinpoint the exact cellular source of protein expression in the cancer tissue context).